TINNITOX - Botulinum toxin A in tinnitus patients with concurrent bruxism and/or jaw muscle myalgia. A triple blind, randomized, placebo-controlled cross-over trial

You likely can't join if

• Participants are excluded from the study if any of the following criteria apply: 1. Participant exhibits pulsatile tinnitus. 2. Participant shows evidence of middle ear disease, chronic middle ear, or mastoid infection assessed by an ENT specialist. 3. Active infection at the sites of injection. 4. Participant has a severe somatic illness or psychiatric disorder that would make the individual unable to comply and participate in the study. 5. Participant has any medical condition that may put the patient at increased risk of exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, Amyotrophic lateral sclerosis, other diseases interfering with neuromuscular function (Felleskatalogen, 2024) or treatment with drugs affecting the neuromuscular junction. 6. Participant has hemophilia or other clotting disorders that cause bleeding diathesis. 7. Participant has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that has been active or required treatment in the past 6 months. 8. Females who are breastfeeding, pregnant, or unwilling to practice adequate contraception throughout the study 9. Participant received treatment with botulinum toxin of any serotype within six months before randomization. 10. Participant has a known allergy to BoNTA. 11. Participant has been immunized for any botulinum toxin serotype. 12. Abuse of alcohol or illicit drugs. 13. Participant has any condition or situation that, in the investigator’s opinion, puts them at significant risk, could confound the study results, and may interfere significantly with the patient’s participation.